Showing 2680 results for "amyotrophic lateral sclerosis (ALS)"

Potential Gene Therapy for ALS and Similar Diseases Licensed to CavoGene LifeSciences

The University California San Diego (UC San Diego) has licensed the right to develop and commercialize an investigational gene therapy for amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease, called SynCav1, to CavoGene LifeSciences. The therapy may also benefit people with traumatic brain and spinal cord injuries, and cognitive decline disorders.

Chip Technology Identifies Potential Combo Therapy for ALS in Study

Chip technology — much like an organ-on-a-chip that can simulate the workings of tissue or organs  — was used to recreate amyotrophic lateral sclerosis (ALS), allowing researchers to identify two treatments for blood cancers — rapamycin plus bosutinib — as a possible ALS combination therapy. The study, “Microphysiological 3D model…

Health Canada Authorizes Radicava for Treatment of ALS

Canadian authorities have approved the sale of Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS). The therapy will be marketed by Mitsubishi Tanabe Pharma Canada (MTP-CA), a unit of Mitsubishi Tanabe Pharma America. MTP-CA was established earlier this year to distribute Radicava and other medicines for difficult-to-treat…

Augmentative and Alternative Communication is Key to Treat Speech Disorders in ALS Patients, Study Shows

Personalized assessment and intervention with a specific communication strategy are key to improving communication in patients with amyotrophic lateral sclerosis (ALS). Dysarthria, the term for a group of speech disorders, affects 95% of patients with ALS. Augmentative and alternative communication (AAC), which includes aided and unaided approaches such as communication books…